BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 28, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Bacteriophage-based, mucosal, needle-free COVID-19 vaccine protects against challenge in vivo
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Infection
Bacteriophage-based, mucosal, needle-free COVID-19 vaccine protects against challenge in vivo
Sep. 20, 2022
No Comments
The development of needle-free mucosal vaccines for SARS-CoV-2 would be advantageous, potentially reducing viral acquisition as well as transmission.
BioWorld Science
Infection
Coronavirus
Vaccine
